- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Graphene Biosensor to Detect Cancer Biomarkers
The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.
An ultrasensitive biosensor made from the wonder material graphene has been used to detect molecules that indicate an increased risk of developing cancer.
The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.
The biosensor has been presented today, 19 September, in IOP Publishing's journal 2D Materials.
To develop a viable bionsensor, the researchers, from the University of Swansea, had to create patterned graphene devices using a large substrate area, which was not possible using the traditional exfoliation technique where layers of graphene are stripped from graphite.
Read the complete story: http://bit.ly/1rhxpVx
SOurce: ScienceDaily
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
